138661-02-6 Usage
Description
Pentetreotide, also known as Octreotide, is a synthetic somatostatin analogue that exhibits a high affinity for somatostatin receptors. It is a colorless to off-white lyophilized solid and is commonly used in the medical field for various therapeutic applications. Pentetreotide works by mimicking the action of somatostatin, which helps regulate the secretion of hormones and inhibits the growth of certain types of cells.
Source:
Pentetreotide is a synthetically produced compound, and its brand name is Monodral Bromide, manufactured by Sterling Winthrop.
Uses
Used in Oncology:
Pentetreotide is used as a diagnostic agent for the detection and localization of neuroendocrine tumors, such as carcinoid tumors and pituitary adenomas. It helps in identifying the presence and extent of these tumors by binding to somatostatin receptors expressed on the tumor cells, allowing for better visualization through imaging techniques like scintigraphy.
Used in Hormone Regulation:
Pentetreotide is used as a therapeutic agent for the management of symptoms associated with hormone-secreting tumors, such as acromegaly and carcinoid syndrome. It helps in controlling the excessive secretion of hormones by binding to somatostatin receptors on the tumor cells, thereby reducing the symptoms and improving the patient's quality of life.
Used in Acute Variceal Bleeding:
Pentetreotide is used as a treatment option for acute variceal bleeding in patients with portal hypertension. It helps in reducing the blood flow to the varices (enlarged veins) and lowering the pressure in the portal vein, thus preventing further bleeding episodes.
Used in Drug Delivery Systems:
Pentetreotide can be used as a targeting moiety in drug delivery systems, particularly for the treatment of neuroendocrine tumors. By conjugating therapeutic agents, such as chemotherapy drugs or radionuclides, to pentetreotide, the drug can be selectively delivered to the tumor cells expressing somatostatin receptors, enhancing the therapeutic efficacy and reducing side effects on healthy tissues.
Check Digit Verification of cas no
The CAS Registry Mumber 138661-02-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,8,6,6 and 1 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 138661-02:
(8*1)+(7*3)+(6*8)+(5*6)+(4*6)+(3*1)+(2*0)+(1*2)=136
136 % 10 = 6
So 138661-02-6 is a valid CAS Registry Number.
InChI:InChI=1/C63H87N13O19S2/c1-37(78)48(34-77)70-62(94)50-36-97-96-35-49(71-58(90)45(25-39-13-5-3-6-14-39)66-51(80)29-75(31-53(83)84)23-21-74(30-52(81)82)22-24-76(32-54(85)86)33-55(87)88)61(93)68-46(26-40-15-7-4-8-16-40)59(91)69-47(27-41-28-65-43-18-10-9-17-42(41)43)60(92)67-44(19-11-12-20-64)57(89)73-56(38(2)79)63(95)72-50/h3-10,13-18,28,37-38,44-50,56,65,77-79H,11-12,19-27,29-36,64H2,1-2H3,(H,66,80)(H,67,92)(H,68,93)(H,69,91)(H,70,94)(H,71,90)(H,72,95)(H,73,89)(H,81,82)(H,83,84)(H,85,86)(H,87,88)/t37-,38-,44+,45-,46+,47-,48-,49+,50+,56+/m1/s1
138661-02-6Relevant articles and documents
Concise site-specific synthesis of DTPA-peptide conjugates: Application to imaging probes for the chemokine receptor CXCR4
Masuda, Ryo,Oishi, Shinya,Ohno, Hiroaki,Kimura, Hiroyuki,Saji, Hideo,Fujii, Nobutaka
experimental part, p. 3216 - 3220 (2011/06/25)
Diethylenetriaminepentaacetic acid (DTPA) is a useful chelating agent for radionuclides such as 68Ga, 99mTc and 111In, which are applicable to nuclear medicine imaging. In this study, we established a facile synthetic prot